pDEST51-LRRK2-WT Citations (3)

Originally described in: The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation
J Biol Chem. 2008 Jun 13;283(24):16906-14. PubMed Journal

---

Articles Citing pDEST51-LRRK2-WT

Articles
A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway. Salasova A, Yokota C, Potesil D, Zdrahal Z, Bryja V, Arenas E. Mol Neurodegener. 2017 Jul 11;12(1):54. doi: 10.1186/s13024-017-0193-9. PubMed
LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair. Chen L, Hou J, Zeng X, Guo Q, Deng M, Kloeber JA, Tu X, Zhao F, Wu Z, Huang J, Luo K, Kim W, Lou Z. Clin Transl Med. 2021 Mar;11(3):e341. doi: 10.1002/ctm2.341. PubMed
NME1 Protects Against Neurotoxin-, alpha-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease. Anantha J, Goulding SR, Tuboly E, O'Mahony AG, Moloney GM, Lomansey G, McCarthy CM, Collins LM, Sullivan AM, O'Keeffe GW. Mol Neurobiol. 2022 Jan;59(1):61-76. doi: 10.1007/s12035-021-02569-6. Epub 2021 Oct 8. PubMed

If you have published an article using this material, please email us at to have your article added to this page.